These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 67714

  • 1. Development of an intravenous gamma-globulin with Fc activities. II. Reconversion of S-sulfonated human gamma-globulin into the original gamma-globulin.
    Masuho Y, Tomibe K, Watanabe T, Fukumoto Y.
    Vox Sang; 1977; 32(5):290-5. PubMed ID: 67714
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. THE ROLE OF DISULFIDE BONDS IN THE COMPLEMENT-FIXING AND PRECIPITATING PROPERTIES OF 7S RABBIT AND SHEEP ANTIBODIES.
    SCHUR PH, CHRISTIAN GD.
    J Exp Med; 1964 Oct 01; 120(4):531-45. PubMed ID: 14212117
    [Abstract] [Full Text] [Related]

  • 4. MOLECULAR BASIS OF PASSIVE SENSITIZATION. II. THE ROLE OF FRAGMENT 3 OF GAMMA-GLOBULIN AND ITS DISULFIDE BONDS IN PASSIVE SENSITIZATION AND COMPLEMENT FIXATION.
    ISHIZAKA K, ISHIZAKA T.
    J Immunol; 1964 Jul 01; 93():59-68. PubMed ID: 14214390
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interaction of S-sulfonated human IgG with human complement and its components.
    Fukumoto Y, Inai S, Nagaki K, Iida K, Yamagami E, Masuho Y, Watanabe T.
    J Biochem; 1977 Oct 01; 82(4):955-60. PubMed ID: 336617
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Prophylaxis and therapy with gamma globulin. General characterization and clinical use of gamma globulin preparations].
    Barandun S, Skvaril F, Morell A.
    Schweiz Med Wochenschr; 1976 Apr 17; 106(16):533-42. PubMed ID: 62393
    [Abstract] [Full Text] [Related]

  • 10. Clinical trial of sulfonated immunoglobulin preparation for intravenous administration. I. Replacement therapy for primary immunodeficiency syndromes.
    Kobayashi N, Gohya N, Matsumoto S.
    Eur J Pediatr; 1981 May 17; 136(2):159-65. PubMed ID: 6164554
    [Abstract] [Full Text] [Related]

  • 11. Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.
    Barandun S, Castel V, Makula MF, Morell A, Plan R, Skvaril F.
    Vox Sang; 1975 May 17; 28(3):157-75. PubMed ID: 47211
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Clinical experiences in the use of intravenously injectable tetanus-immune human gamma globulin TIG(i). II. Clinical and side effects (author's transl)].
    Ebisawa I, Kurosu Y, Otsuka T, Matsuhashi C, Yamamoto A.
    Kansenshogaku Zasshi; 1981 Feb 17; 55(2):101-8. PubMed ID: 6167648
    [No Abstract] [Full Text] [Related]

  • 14. Intravenous gamma globulin. I. Background.
    Baumgarten W.
    Vox Sang; 1967 Jul 17; 13(1):84-5. PubMed ID: 4166593
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Measurement of the anti-complementary activity of gamma-globulin preparations for intravenous administration].
    Malgras J, Hauptmann G, Zorn JJ, Waitz R.
    Rev Fr Transfus; 1970 Jun 17; 13(2):173-80. PubMed ID: 4100946
    [No Abstract] [Full Text] [Related]

  • 17. The preparation of plasmin treated immune serum globulin for intravenous use.
    Sgouris JT.
    Vox Sang; 1967 Jul 17; 13(1):71-84. PubMed ID: 4166592
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.